This Article
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Molloy, D. W.
Right arrow Articles by Singer, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Molloy, D. W.
Right arrow Articles by Singer, J.
Related Collections
Right arrow Dementia

Canadian Medical Association Journal, Vol 144, Issue 1 29-34, Copyright © 1991 by Canadian Medical Association

CLINICAL TRIAL

Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease

D. W. Molloy, G. H. Guyatt, D. B. Wilson, R. Duke, L. Rees and J. Singer
Department of Medicine, McMaster University, Hamilton, Ont.

OBJECTIVE: To determine the efficacy of tetrahydroaminoacridine (THA) in Alzheimer's disease. DESIGN: Randomized, double-blind, multiple crossover trial with three treatment periods, each consisting of 3 weeks of active drug therapy and 3 weeks of placebo administration. SETTING: Referral-based geriatric practice in a community hospital. PATIENTS: Thirty-four patients with moderate to severe Alzheimer's disease. Subjects were included if they had stage 3 to 6 disease (as determined by the Reisberg scale) and had not been taking psychotropic drugs for at least 1 month and if informed consent had been obtained from the patients and their next of kin. INTERVENTIONS: Fifty to 100 mg of THA daily and matched placebo. RESULTS: Of the initial 34 patients 14 experienced liver toxicity and 3 gastrointestinal side effects during the study; however, all 22 who completed the study were able to tolerate at least the minimum dose. For the 22 patients there was no clinically or statistically significant effect of THA on cognition, functional status or behaviour. The results for individual patients showed no subgroup of THA-responsive patients. CONCLUSION: THA has no clinically important benefits in Alzheimer's disease and is associated with appreciable toxic effects.


This article has been cited by other articles:


Home page
 JAMAHome page
N.-H. Trinh, J. Hoblyn, S. Mohanty, and K. Yaffe
Efficacy of Cholinesterase Inhibitors in the Treatment of Neuropsychiatric Symptoms and Functional Impairment in Alzheimer Disease: A Meta-analysis
JAMA, January 8, 2003; 289(2): 210 - 216.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
W. Pryse-Phillips
Do We Have Drugs for Dementia?: No
Arch Neurol, June 1, 1999; 56(6): 735 - 737.
[Full Text] [PDF]

Home page
 JAMAHome page
N. Qizilbash, A. Whitehead, J. Higgins, G. Wilcock, L. Schneider, M. Farlow, and for the Dementia Trialists' Collaboration
Cholinesterase Inhibition for Alzheimer Disease: A Meta-analysis of the Tacrine Trials
JAMA, November 25, 1998; 280(20): 1777 - 1782.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
M. Eccles, J. Clarke, M. Livingston, N. Freemantle, and J. Mason
North of England evidence based guidelines development project: guideline for the primary care management of dementia
BMJ, September 19, 1998; 317(7161): 802 - 808.
[Full Text] [PDF]

Home page
 BMJHome page
N Maltby, G A Broe, H Creasey, A F Jorm, H Christensen, and W S Brooks
Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial
BMJ, April 2, 1994; 308(6933): 879 - 883.
[Abstract] [Full Text]

Home page
 JAMAHome page
M. Farlow, S. I. Gracon, L. A. Hershey, K. W. Lewis, C. H. Sadowsky, J. Dolan-Ureno, the Tacrine Study Group, S. W. Asher, C. Beaver, D. Hamilton, et al.
A Controlled Trial of Tacrine in Alzheimer's Disease
JAMA, November 11, 1992; 268(18): 2523 - 2529.
[Abstract] [PDF]